drugset
drugset / Trial / NCT03349723

This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy Men

NCT03349723 ↗

Phase 1 Completed 57 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The primary objective of this trial is to investigate the safety and tolerability of BI 1265162 in healthy male subjects following inhalative administration of single rising doses. Secondary objective is the exploration of the pharmacokinetics (PK) of BI 1265162 after single dosing.

Timeline

Start
2017-11-23
Primary completion
2018-03-05
Completion
2018-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1265162 Unknown — Inhaled

Indications

No indication recorded.